High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome

被引:20
|
作者
Lundin, Catarina [1 ]
Hjorth, Lars [2 ]
Behrendtz, Mikael [3 ]
Nordgren, Ann [4 ]
Palmqvist, Lars [5 ]
Andersen, Mette Klarskov [6 ]
Biloglav, Andrea [1 ]
Forestier, Erik [7 ]
Paulsson, Kajsa [1 ]
Johansson, Bertil [1 ]
机构
[1] Lund Univ, Skane Univ Hosp, Univ & Reg Labs, Dept Clin Genet, SE-22185 Lund, Sweden
[2] Skane Univ Hosp, Dept Pediat, Lund, Sweden
[3] Linkoping Univ Hosp, Dept Pediat, S-58185 Linkoping, Sweden
[4] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[5] Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, Gothenburg, Sweden
[6] Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark
[7] Umea Univ, Dept Clin Sci, Umea, Sweden
来源
GENES CHROMOSOMES & CANCER | 2012年 / 51卷 / 02期
基金
瑞典研究理事会;
关键词
ACUTE MYELOID-LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; BFM STUDY-GROUP; MEGAKARYOBLASTIC LEUKEMIA; CLINICAL CHARACTERISTICS; GLUCOCORTICOID-RECEPTOR; GENETIC ALTERATIONS; TUMOR-SUPPRESSOR; B-PROGENITOR; EXPRESSION;
D O I
10.1002/gcc.20944
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous cytogenetic studies of myeloid and acute lymphoblastic leukemias in children with Down syndrome (ML-DS and DS-ALL) have revealed significant differences in abnormality patterns between such cases and acute leukemias in general. Also, certain molecular genetic aberrations characterize DS-related leukemias, such as GATA1 mutations in ML-DS and deregulation of the CRLF2 gene in DS-ALL. Whether microdeletions/microduplications also vary between DS and non-DS cases is presently unclear. To address this issue, we performed single nucleotide polymorphism array analyses of eight pediatric ML-DS and 17 B-cell precursor DS-ALL. In the ML-DS cases, a total of 29 imbalances (20 gains and nine losses) and two partial uniparental isodisomies (pUPDs) were detected. None of the 11 small (defined as <10 Mb) imbalances were recurrent, nor were the pUPDs, whereas of the 18 large aberrations, three were recurrentdup(1q), +8 and +21. In contrast, several frequent changes were identified in the DS-ALL cases, which harbored 82 imbalances (30 gains and 52 losses) and four pUPDs. Of the 40 large changes, 28 were gains and 12 losses, with +X, dup(Xq), dup(1q), del(7p), dup(8q), del(9p), dup(9p), del(12p), dup(17q), and +21 being recurrent. Of the 40 microdeletions identified, several targeted specific genes, with the following being repeatedly deleted: BTG1 and CDKN2A/B (29% of cases), ETV6, IKZF1, PAX5 and SERP2 (18%), and BTLA, INPP4B, P2RY8, and RB1 (12%). Loss of the SERP2 and INPP4B genes, encoding the stress-associated endoplasmic reticulum protein family member 2 and the inositol polyphosphate 4-phosphatase-II, respectively, has previously never been implicated in leukemia. Although deletions of the other genes have been associated with ALL, the high frequency of BTG1 loss is a novel finding. Such deletions may characterize a clinical subgroup of DS-ALL, comprising mainly boys with a high median age. In conclusion, ML-DS and DS-ALL are genetically distinct, with mainly gains in ML-DS and deletions in DS-ALL. Furthermore, DS-ALL is characterized by several recurrent gene deletions, with BTG1 loss being particularly frequent. (C) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:196 / 206
页数:11
相关论文
共 50 条
  • [41] Epigenome-Wide Association Study of Acute Lymphoblastic Leukemia in Children with Down Syndrome
    Li, Shaobo
    Sok, Pagna
    Xu, Keren
    Muskens, Ivo S.
    Elliott, Natalina
    Myint, Swe Swe
    Pandey, Priyatama
    Hansen, Helen M.
    Morimoto, Libby M.
    Kang, Alice Y.
    Metayer, Catherine
    Ma, Xiaomei
    Mueller, Beth A.
    Roy, Anindita
    Roberts, Irene
    Rabin, Karen R.
    Brown, Austin L.
    Lupo, Philip J.
    Wiemels, Joseph L.
    de Smith, Adam J.
    BLOOD, 2021, 138
  • [42] Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia
    C Bohnstedt
    M Levinsen
    S Rosthøj
    B Zeller
    M Taskinen
    S Hafsteinsdottir
    H Björgvinsdóttir
    M Heyman
    K Schmiegelow
    Leukemia, 2013, 27 : 866 - 870
  • [43] Epigenome-wide association study of acute lymphoblastic leukemia in children with Down syndrome
    Li, Shaobo
    Sok, Pagna
    Xu, Keren
    Muskens, Ivo S.
    Elliott, Natalina
    Myint, Swe Swe
    Pandey, Priyatama
    Hansen, Helen M.
    Morimoto, Libby M.
    Kang, Alice Y.
    Metayer, Catherine
    Ma, Xiaomei
    Mueller, Beth A.
    Roy, Anindita
    Roberts, Irene
    Rabin, Karen R.
    Brown, Austin L.
    Lupo, Philip J.
    Wiemels, Joseph L.
    de Smith, Adam J.
    BLOOD ADVANCES, 2022, 6 (14) : 4132 - 4136
  • [44] Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome
    Brown, Austin L.
    de Smith, Adam J.
    Scheurer, Michael E.
    Kallsen, Noah A.
    Peyton, Shanna A.
    Davies, Gareth E.
    Ehli, Erik A.
    Zwick, Michael E.
    Winick, Naomi
    Maloney, Kelly
    Angiolillo, Anne L.
    Schore, Reuven
    Burke, MIchael M.
    Salzer, Wanda L.
    Heerema, Nyla A.
    Carroll, Andrew J.
    Borowitz, Michael J.
    Wood, Brent L.
    Carroll, William L.
    Raetz, Elizabeth A.
    Feingold, Elanor
    Sherman, Stephanie L.
    Yang, Wenjian
    Devidas, Meenakshi
    Walsh, Kyle
    DeWan, Andrew T.
    Pombo-de-Oliveira, Maria S.
    Taub, Jeffrey W.
    Sinnett, Daniel
    Healy, Jasmine
    Birch, Jillian M.
    Barcellos, Lisa F.
    Hansen, Helen
    Smirnov, Ivan
    Mullighan, Charles G.
    Hunger, Stephen P.
    Pui, Ching-Hon
    Loh, Mignon
    Wiemels, Joe L.
    Ma, Xiaomei
    Metayer, Catherine
    Mueller, Beth A.
    Relling, Mary V.
    Yang, Jun J.
    Lupo, Philip J.
    Rabin, Karen R.
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Outcome of Acute Lymphoblastic Leukemia in Children with Down Syndrome: Report from a Single Institution
    Ahmed, Abdullateef
    Bayoumy, Mohamed
    Yassin, Fawwaz
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S37 - S37
  • [46] Healthcare utilization and costs associated with acute lymphoblastic leukemia in children with and without Down syndrome
    Athale, Uma
    Sutradhar, Rinku
    Breakey, Vicky R.
    Li, Qing
    Bassal, Mylene
    Gibson, Paul
    Patel, Serina
    Wheaton, Laura
    Pole, Jason D.
    Mittman, Nicole
    Pechlivanoglou, Petros
    Gupta, Sumit
    PEDIATRIC BLOOD & CANCER, 2022, 69 (10)
  • [47] A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia
    Page, Elyse C.
    Heatley, Susan L.
    Yeung, David T.
    Thomas, Paul Q.
    White, Deborah L.
    BLOOD, 2019, 134
  • [48] XYY syndrome in children with acute lymphoblastic leukemia
    Sandlund, JT
    Krance, R
    Pui, CH
    Hancock, M
    Crist, WM
    Filatov, LV
    Raimondi, SC
    MEDICAL AND PEDIATRIC ONCOLOGY, 1997, 28 (01): : 6 - 8
  • [49] Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients
    Scheijen, Blanca
    Boer, Judith M.
    Marke, Rene
    Tijchon, Esther
    Schenau, Dorette van Ingen
    Waanders, Esme
    van Emst, Liesbeth
    van der Meer, Laurens T.
    Pieters, Rob
    Escherich, Gabriele
    Horstmann, Martin A.
    Sonneveld, Edwin
    Venn, Nicola
    Sutton, Rosemary
    Dalla-Pozza, Luciano
    Kuiper, Roland P.
    Hoogerbrugge, Peter M.
    den Boer, Monique L.
    van Leeuwen, Frank N.
    HAEMATOLOGICA, 2017, 102 (03) : 541 - 551
  • [50] PRESENTATION AND OUTCOME OF CHILDREN WITH DOWN SYNDROME AND ACUTE LYMPHOBLASTIC LEUKEMIA IN THE EORTC CHILDREN'S LEUKEMIA GROUP PROTOCOL 58951
    Mondelaers, V.
    De Moerloose, B.
    Suciu, S.
    Ferster, A.
    Lutz, P.
    Uyttebroeck, A.
    Plantaz, D.
    Norton, L.
    Sirvent, N.
    Robert, A.
    Philippet, P.
    Mazingue, F.
    Yakouben, K.
    Munzer, M.
    Millot, F.
    Rohrlich, P.
    Baila, L.
    Bertrand, Y.
    Benoit, Y.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 260 - 260